title: Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
abstract: BACKGROUND
  The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms.
  
  
  OBJECTIVE
  We sought to evaluate and provide guidance on the diagnosis and clinical management of dermatologic symptoms associated with sorafenib in patients with advanced solid tumors.
  
  
  METHODS
  English-language studies representative of a patient population with a variety of tumor types, who received single-agent sorafenib, were selected. Particular emphasis was placed on the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs).
  
  
  RESULTS
  Frequently observed dermatologic side effects (any grade in TARGETs) of sorafenib include rash/desquamation (40%), hand-foot skin reaction (30%), alopecia (27%), and pruritus (19%). Generally, dermatologic symptoms resolve with appropriate management, including topical treatments, dose interruptions, dose reductions, or a combination of these.
  
  
  CONCLUSIONS
  The results presented here are based on a limited number of studies.
  
  
  CONCLUSIONS
  Although sorafenib is associated with dermatologic symptoms, these are usually resolved with appropriate intervention, patient-led practical treatment, and preventative measures.
authors.affiliation: Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France. crobert@igr.fr
authors.forename: Caroline
authors.initials: C
authors.lastname: Robert
authors.forename: Christina
authors.initials: C
authors.lastname: Mateus
authors.forename: Alain
authors.initials: A
authors.lastname: Spatz
authors.forename: Janine
authors.initials: J
authors.lastname: Wechsler
authors.forename: Bernard
authors.initials: B
authors.lastname: Escudier
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib